Three-Season Influenza Vaccine Immune Response Data for 1,328 Participants

A three-season (2022–2025) study of 1,328 participants aged 9–89 years receiving six different influenza vaccine types. Serum samples were tested for hemagglutination inhibition activity against vaccine and historical strains before and after vaccination. The dataset, authored by Engin Berber and published on figshare, analyzes seroprotection and seroconversion rates by age group and vaccine platform.

Use Cases

• Compare antibody response effectiveness across six vaccine types based on hemagglutination inhibition activity data.
• Analyze the impact of age on seroprotection and seroconversion rates based on participant age groups from 9 to 89.
• Study the effect of repeated annual vaccination on immune outcomes based on data from three consecutive seasons.
• Evaluate differences in immune response between younger adults and elderly participants based on post-vaccination HAI titers.

Strengths

• Includes 1,328 participants, providing a substantial sample size.
• Covers three consecutive seasons (2022–2025), allowing longitudinal analysis.
• Compares six distinct vaccine types (Fluzone SD/HD, Fluad, Flucelvax, Flublok, Flumist).
• Includes pre- and post-vaccination serum measurements for hemagglutination inhibition activity.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is 97.0 KB, indicating a limited scope and likely aggregated summary data rather than raw individual measurements.

Provenance

Source

figshare

Collection Method

Clinical study collecting serum samples and testing for hemagglutination inhibition activity.

Time Range

2022–2025

Freshness

Last updated 2026-04-16 17:37:34; freshness should be verified.